DE69612575T2 - Hocheffiziente Übersetzung von mRNA Molukülen - Google Patents

Hocheffiziente Übersetzung von mRNA Molukülen

Info

Publication number
DE69612575T2
DE69612575T2 DE69612575T DE69612575T DE69612575T2 DE 69612575 T2 DE69612575 T2 DE 69612575T2 DE 69612575 T DE69612575 T DE 69612575T DE 69612575 T DE69612575 T DE 69612575T DE 69612575 T2 DE69612575 T2 DE 69612575T2
Authority
DE
Germany
Prior art keywords
highly efficient
mrna molecules
efficient translation
translation
mrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69612575T
Other languages
English (en)
Other versions
DE69612575D1 (de
Inventor
David W Andrews
Akaterini Vassilakos
Martin John Glenton Hughes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McMaster University
Original Assignee
McMaster University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McMaster University filed Critical McMaster University
Application granted granted Critical
Publication of DE69612575D1 publication Critical patent/DE69612575D1/de
Publication of DE69612575T2 publication Critical patent/DE69612575T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
DE69612575T 1995-02-10 1996-02-12 Hocheffiziente Übersetzung von mRNA Molukülen Expired - Fee Related DE69612575T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/386,921 US5824497A (en) 1995-02-10 1995-02-10 High efficiency translation of mRNA molecules

Publications (2)

Publication Number Publication Date
DE69612575D1 DE69612575D1 (de) 2001-05-31
DE69612575T2 true DE69612575T2 (de) 2001-10-18

Family

ID=23527635

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69612575T Expired - Fee Related DE69612575T2 (de) 1995-02-10 1996-02-12 Hocheffiziente Übersetzung von mRNA Molukülen

Country Status (4)

Country Link
US (2) US5824497A (de)
EP (1) EP0726319B1 (de)
CA (1) CA2169317A1 (de)
DE (1) DE69612575T2 (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002508299A (ja) * 1997-09-19 2002-03-19 セクイター， インク． センスｍＲＮＡ治療
EP1892299A3 (de) * 1997-09-19 2011-07-20 Life Technologies Corporation Sense mRNA therapie
WO2001048480A1 (en) * 1999-12-28 2001-07-05 Keene Jack D METHODS FOR ISOLATING AND CHARACTERIZING ENDOGENOUS mRNA-PROTEIN (mRNP) COMPLEXES
US8815517B2 (en) * 1999-12-28 2014-08-26 Ribonomics, Inc. Methods for identifying functionally related genes and drug targets
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
US20030166282A1 (en) 2002-02-01 2003-09-04 David Brown High potency siRNAS for reducing the expression of target genes
CA2474910A1 (en) 2002-02-01 2003-08-07 Sequitur, Inc. Oligonucleotide compositions with enhanced efficiency
AU2002953015A0 (en) * 2002-12-02 2002-12-12 Women's And Children's Hospital Modified lacz gene
WO2004111243A1 (en) * 2003-06-19 2004-12-23 Carbozyme Oy Stabilisation of mrna transcripts
ES2937245T3 (es) 2005-08-23 2023-03-27 Univ Pennsylvania ARN que contiene nucleósidos modificados y métodos de uso del mismo
US9012219B2 (en) * 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
DE102005046490A1 (de) * 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US9249423B2 (en) * 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
US8859229B2 (en) * 2007-02-02 2014-10-14 Yale University Transient transfection with RNA
EP2421563B1 (de) * 2009-04-22 2017-04-12 Massachusetts Institute of Technology Immanente immunsuppression zur wiederholten abgabe von langen rna-molekülen
US10837020B2 (en) 2009-04-22 2020-11-17 Massachusetts Institute Of Technology Innate immune suppression enables repeated delivery of long RNA molecules
DK3112467T3 (en) 2009-12-07 2018-04-23 Univ Pennsylvania RNA PREPARATIONS COMPREHENSIVE PURIFIED MODIFIED RNA FOR CELL PROGRAMMING
SG181601A1 (en) 2009-12-10 2012-07-30 Univ Minnesota Tal effector-mediated dna modification
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK3590949T3 (da) 2010-10-01 2022-07-11 Modernatx Inc Ribonukleinsyrer indeholdende n1-methyl-pseudouracil og anvendelse heraf
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SG10201602654SA (en) 2011-10-03 2016-05-30 Moderna Therapeutics Inc Modified nucleosides,nucleotides,and nucleic acids,and uses thereof
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
WO2013090648A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
DK3421601T3 (da) 2011-12-30 2020-02-24 Cellscript Llc Fremstilling og anvendelse af in-vitro-syntetiseret ssRNA til indføring i pattedyrceller med henblik på at inducere en biologisk eller biokemisk effekt
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
JP2015516143A (ja) 2012-04-02 2015-06-08 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
AU2013331351A1 (en) * 2012-10-16 2015-04-30 Massachusetts Institute Of Technology Production of stable non-polyadenylated RNAs
LT2922554T (lt) 2012-11-26 2022-06-27 Modernatx, Inc. Terminaliai modifikuota rnr
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
JP6625521B2 (ja) * 2013-05-15 2020-01-08 リボカイン，エルエルシー 環状ｒｎａの細胞内翻訳
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
AU2014329452B2 (en) 2013-10-03 2019-06-20 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
CN106659803A (zh) 2014-04-23 2017-05-10 摩登纳特斯有限公司 核酸疫苗
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US10626413B2 (en) * 2016-01-15 2020-04-21 Enyu Ding Nucleic acid vector
WO2018144775A1 (en) 2017-02-01 2018-08-09 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
WO2018213789A1 (en) 2017-05-18 2018-11-22 Modernatx, Inc. Modified messenger rna comprising functional rna elements
EP3638292A1 (de) 2017-06-14 2020-04-22 ModernaTX, Inc. Für koagulationsfaktor viii kodierende polynukleotide
WO2019104195A1 (en) 2017-11-22 2019-05-31 Modernatx, Inc. Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia
US11859215B2 (en) 2017-11-22 2024-01-02 Modernatx, Inc. Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
EP3714047A2 (de) 2017-11-22 2020-09-30 ModernaTX, Inc. Polynukleotide codierend für phenylalaninhydroxylase zur behandlung von phenylketonurie
US20210163928A1 (en) 2018-04-11 2021-06-03 Modernatx, Inc. Messenger rna comprising functional rna elements
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
US20220110966A1 (en) 2018-09-02 2022-04-14 Modernatx, Inc. Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency
EP3849594A2 (de) 2018-09-13 2021-07-21 Modernatx, Inc. Für verzweigtkettige alpha-ketosäuredehydrogenasekomplexe e1-alpha, e1-beta und e2 untereinheiten codierende polynukleotide zur behandlung von ahornsirupkrankheit
CN113164561A (zh) 2018-09-13 2021-07-23 摩登纳特斯有限公司 用于治疗糖原贮积病的编码葡萄糖-6-磷酸酶的多核苷酸
US20220401584A1 (en) 2018-09-14 2022-12-22 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
EP3856233A1 (de) 2018-09-27 2021-08-04 Modernatx, Inc. Arginase-1-codierende polynukleotide zur behandlung von arginasemangel
EP3965797A1 (de) 2019-05-08 2022-03-16 AstraZeneca AB Zusammensetzungen für haut und wunden und verwendungsverfahren dafür
WO2020263985A1 (en) 2019-06-24 2020-12-30 Modernatx, Inc. Messenger rna comprising functional rna elements and uses thereof
JP2022552371A (ja) 2019-10-15 2022-12-15 モデルナティエックス インコーポレイテッド 免疫調節ポリペプチドをコードするｍＲＮＡ及びその使用
WO2021076811A1 (en) 2019-10-15 2021-04-22 Moderna TX, Inc. Mrnas encoding granulocyte-macrophage colony stimulating factor for treating parkinson's disease
JP7451705B2 (ja) * 2019-11-26 2024-03-18 コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジー タンパク質発現用ｍＲＮＡ構造体及びその用途
AU2021205337A1 (en) 2020-01-10 2022-07-21 Modernatx, Inc. Methods of making tolerogenic dendritic cells
EP4096720A2 (de) 2020-01-30 2022-12-07 ModernaTX, Inc. Für metabolische umprogrammierungspolypeptide codierende mrnas und deren verwendungen
EP4149435A1 (de) 2020-05-14 2023-03-22 Modernatx, Inc. Lnp-zusammensetzungen mit einem mrna-therapeutikum und einem effektormolekül
US20230235298A1 (en) 2020-06-01 2023-07-27 Modernatx, Inc. Phenylalanine hydroxylase variants and uses thereof
US20230242908A1 (en) 2020-06-23 2023-08-03 Modernatx, Inc. Lnp compositions comprising mrna therapeutics with extended half-life
WO2022204371A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
WO2022204369A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
WO2022204380A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
WO2022204390A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
WO2022204370A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency
KR20220159909A (ko) * 2021-05-25 2022-12-05 한국생명공학연구원 단백질 발현용 mRNA 제조방법 및 이에 의해 제조된 mRNA의 용도
WO2022271776A1 (en) 2021-06-22 2022-12-29 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
WO2023056044A1 (en) 2021-10-01 2023-04-06 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
WO2023196399A1 (en) 2022-04-06 2023-10-12 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding argininosuccinate lyase for the treatment of argininosuccinic aciduria
CN117165611A (zh) * 2022-05-27 2023-12-05 深圳市三源生生物科技有限公司 一种构建mRNA体外转录模板的骨架

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1209501A (en) * 1982-09-16 1986-08-12 Nikos Panayotatos Expression vector
US5079159A (en) * 1983-12-27 1992-01-07 Genetics Institute, Inc. Method for making tissue plasminogen activator
US4740461A (en) * 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5149635A (en) * 1986-09-12 1992-09-22 Abbott Biotech, Inc. Messenger RNA stabilization in animal cells
US5026639A (en) * 1988-01-14 1991-06-25 Nippon Mining Company, Limited Method to improve mRNA translation and use thereof for production of platelet factor-4
DE69033628T2 (de) * 1989-10-31 2001-04-19 Monsanto Co Promotor für transgene Pflanzen
US5593874A (en) * 1992-03-19 1997-01-14 Monsanto Company Enhanced expression in plants
US5362865A (en) * 1993-09-02 1994-11-08 Monsanto Company Enhanced expression in plants using non-translated leader sequences

Also Published As

Publication number Publication date
US5824497A (en) 1998-10-20
DE69612575D1 (de) 2001-05-31
US5807707A (en) 1998-09-15
EP0726319A3 (de) 1997-10-22
EP0726319A2 (de) 1996-08-14
EP0726319B1 (de) 2001-04-25
CA2169317A1 (en) 1996-08-11

Similar Documents

Publication Publication Date Title
DE69612575T2 (de) Hocheffiziente Übersetzung von mRNA Molukülen
DE69533361D1 (de) Umsetzung von kohlenwasserstoffen
DE69608448T2 (de) Reduktion des biobewuchses
PT988265E (pt) Processamento de aromaticos pesados
DE19882126T1 (de) Hydrierung von Kohlenwasserstoffen
DE69626729D1 (de) Kombination von Datenwerten
DE69628195D1 (de) Verwendung von xyloglucanendotransglycosylase
DE69632258D1 (de) Verminderung von schlechten geruchen
DE69519381T2 (de) Modifizierung von ölen
ATA136995A (de) Abreicherung von 7-adca in 3-vinyl-aca
DE59705708D1 (de) Lagebestimmung von peripherieeinheiten
DE69709159T2 (de) Kreuz-dimierisierung von olefinen
DE59607408D1 (de) Mischungen von Monoazopyridonfarbstoffen
DE69605708D1 (de) Reinigung von Pentafluorethan
DE29509987U1 (de) Bausatz von Steckverbindern
DE69515021T2 (de) Ausrichtung von Interferometern
DE69611224D1 (de) Verringerung von videomoire
DE59501871D1 (de) Monocarbonsäureamide von Polyaminen
DE29622383U1 (de) Verbindungsanordnung von Bauelementen
DE69804782D1 (de) Isomerisierung von fluorkohlenwasserstoffen
DE69713192T2 (de) Kombination von Enzymen
DE862581T1 (de) Heparinchromatographie von erythropoietinen
SE9502596D0 (sv) New DNA molecules II
KR960027486U (ko) 조명등의 회전구조
IS4339A (is) Hömlun ljóssundurliðunar á 3-setnum-2-oxindólum

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee